Repository logo
 

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus.

Published version
Peer-reviewed

Type

Article

Change log

Authors

O'Brien, John T 
Chouliaras, Leonidas 
Sultana, Janet 
Taylor, John-Paul 
Ballard, Clive 

Abstract

Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson's disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.

Description

Keywords

Humans, Lewy Body Disease, Dementia, Drug Repositioning, Delphi Technique, Parkinson Disease

Journal Title

Alzheimers Res Ther

Conference Name

Journal ISSN

1758-9193
1758-9193

Volume Title

14

Publisher

BioMed Central
Sponsorship
National Institute for Health and Care Research (IS-BRC-1215-20014)
Cambridge NIHR Cambridge Biomedical Research Centre, NIHR Newcastle Biomedical Research Centre